Establishing correlation between in vitro potency and in vivo immunogenicity for mRNA vaccines
Author:
Preprint
- 24 February 2025
- preprint
- Published by F1000 Research Ltd in VeriXiv
Abstract
No abstract availableAll Related Versions
- Version 1, 2025-02-24, VeriXiv
- Published version: npj Vaccines, 10 (1), 1.
Funding Information
- Bill and Melinda Gates Foundation (INV-030762)
This publication has 46 references indexed in Scilit:
- A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infectionMolecular Therapy - Methods & Clinical Development, 2023
- In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacyBiomedicine & Pharmacotherapy, 2023
- Determination of mRNA copy number in degradable lipid nanoparticles via density contrast analytical ultracentrifugationEuropean Biophysics Journal, 2023
- The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infectionCell, 2023
- Impact of lipid nanoparticle size on mRNA vaccine immunogenicityJournal of Controlled Release, 2021
- Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased TransmissibilityJournal of Molecular Biology, 2021
- Encapsulation state of messenger RNA inside lipid nanoparticlesBiophysical Journal, 2021
- Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation LoopJournal of Molecular Biology, 2020
- Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapyCytotherapy, 2018
- Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins2013